drugset / Trial / NCT00800956

Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine

NCT00800956

Phase 1 Completed 4 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of the study is to learn more about how esreboxetine is handled by the body i.e. the absorption, metabolism and excretion of esreboxetine.

Timeline

Start
2009-01
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject [S,S]-Reboxetine Unknown 6 mg Oral

Indications

No indication recorded.